Blog Page 90

Antibacterials: a dying trade
: Despite strong worldwide demand for effective antibacterial products, sustaining growth within this segment will become a challenging task for major pharmaceutical companies. Currently only six marketed drugs have sales of greater than $1 billion and by 2011, 12 out of 29 key products will face patent expiry. A relatively sparse R&D pipeline will do little to replace older products.

Can Your Genomics Work Contribute to Biodefense
Three years ago, Luis Villarreal, a virologist at the University of California, Irvine, came up with the idea of using in vitro gene activation by PCR to study the proteome of a virus in hopes of developing a high-throughput platform for identifying new vaccines.

Villarreal and his collaborators at the university saw infectious disease as their primary target, but after the anthrax attacks in late 2001 they realized that their work might just as easily apply to tackling bioterror agents…